v3.26.1
Commitments and Contingencies (Details) - License Agreements [Member] - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Apr. 08, 2016
Jan. 31, 2025
Mar. 31, 2026
Commitments and Contingencies [Line Items]      
Issuance of shares 882,353 277,823  
License upfront fee paid $ 70    
Percentage of patent net sales 3.50%    
Percentage royalty of net sales     1.75%
Percentage of sublicensee’s net sales     1.75%
Percentage of non-royalty consideration     7.50%
Other expenses $ 50    
Milestones for orphan indication     $ 75
Milestones for a non-orphan indication     $ 650
Food and Drug Administration [Member]      
Commitments and Contingencies [Line Items]      
Other expenses $ 100